Table 1.
Compound | In Vitro Model | In Vivo Model | Dose/ Duration |
Neuroprotective Roles | Reference |
---|---|---|---|---|---|
Ellagic acid (EA), Urolithins A, B, C and D | Human umbilical vein endothelial cells (HUVECs) | - | 10 µM | Anti-atherogenic effects | Mele et al., 2016 [190] |
Punicalagin | Primary mixed glial cells, organotypic hippocampal slice cultures | - | 5–40 µM | Anti-inflammatory effects | Olajide et al., 2014 [191] |
Urolithin A/B | - | C. elegans | 10 µg/mL | Anti-Aβ fibrillation effects | Yuan et al., 2016 [171] |
Pomegranate (freeze dried) | SK-N-SH cells | - | 50–200 ppm |
Anti-inflammatory effects Inhibition of BACE1 and Aβ |
Velagapudi et al., 2016 [192] |
Pomegranate- (pulp hydroalcoholic extract juice, pulp aqueous extract) | PC12 | - | 800 μg/mL 6 h/12 h |
Antioxidant activity Anti-apoptogenic activity |
Forouzanfar et al., 2013 [193] |
Pomegranate peel extract | - | Male C57Bl/6 mice | 800 mg/kg/day for 35 days | Reduction of Aβ plaque density, lipid peroxidation Anti-inflammatory effects Increase in the expression of neurotrophin BDNF |
Morzelle et al., 2016 [194] |
Pomegranate extract | PC12 | mice | 800 mg/kg/day | Antioxidant effects Inhibition of Aβ-induced learning and memory deficiency |
Choi et al., 2015 [195] |
Pomegranate (freeze dried) | - | Transgenic mice APPsw/Tg2576 | 4% fruit diet | Antioxidant activity | Subash et al., 2014 [196] |
Urolithin A/B | MCF7 | - | 40 µM | Estrogenic and anti-estrogenic activity | Larrosa et al., 2006 [140] |
Urolithin A/B | SK-N-MC | - | 10 μM | Antiglycative activity | Verzelloni et al., 2011 [197] |
Urolithins A/B | BV2 murine microglia and SH-SY5Y non-contact, co-culture model | - | 10 μM | Anti-neuroinflammatory activity | DaSilva et al., 2017 [198] |
Urolithins A/B | BV2 murine microglia | - | 3–30 μM | Anti-neuroinflammatory activity | Xu et al., 2018 [199] |